Keyphrases
Cryptococcal Meningitis
100%
Cryptococcal Antigenemia
65%
Cryptococcal Antigen
43%
Titer
43%
Liposomal Amphotericin B
43%
Uganda
35%
Meningitis
30%
Early Fungicidal Activity
27%
Cerebrospinal Fluid
27%
People Living with HIV (PLHIV)
25%
Non-HIV Cryptococcal Meningitis
23%
Flucytosine
22%
Hyponatremia
21%
Amphotericin B
21%
Cryptococcus Neoformans
21%
Antifungal Susceptibility
21%
5-Flucytosine
21%
C-reactive Protein
21%
Risk Factors
21%
HIV-associated
21%
Effect Modifier
21%
Cerebrospinal Fluid Protein
21%
Protein Level
21%
Clinical Significance
21%
Amphotericin B Deoxycholate
21%
Prospective Cohort Study
21%
Fluconazole
19%
Cryptococcus
16%
Minimum Inhibitory Concentration
16%
Confidence Interval
12%
Oral Amphotericin B
10%
Concentration Ratio
10%
AIDS/HIV
9%
Free Survival
8%
Monotherapy
7%
Antifungal Activity
7%
Mortality Risk
5%
Mortality Factors
5%
Human Immunodeficiency
5%
Independent Risk Factors
5%
Nanocrystals
5%
MIC50
5%
Combination Therapy
5%
Lipids
5%
Tandem Mass Spectrometry
5%
Cryptococcosis
5%
Novel Drug Delivery
5%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
5%
Randomized Clinical Trial
5%
Candida Albicans (C. albicans)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cryptococcal Meningitis
95%
HIV
58%
Amphotericin B
56%
Amphotericin
43%
Flucytosine
33%
Meningitis
26%
C Reactive Protein
21%
Prospective Cohort Study
21%
Amphotericin B Deoxycholate
21%
Cryptococcus neoformans
21%
Fluconazole
21%
Cytokine
13%
Minimum Inhibitory Concentration
13%
Filobasidiella
13%
Antifungal Activity
7%
Clinical Trial
6%
Monotherapy
6%
Medicine and Dentistry
Cryptococcal Meningitis
95%
Human Immunodeficiency Virus
72%
Amphotericin
43%
Cerebrospinal Fluid
34%
Amphotericin B
34%
Meningitis
31%
Hyponatremia
21%
Antifungal Susceptibility
21%
Flucytosine
21%
C Reactive Protein
21%
Prospective Cohort Study
21%
Fluconazole
21%
Single Drug Dose
21%
Immune Deficiency
5%